2 08, 2018

Alzheimer’s Agent, BAN2401, Shows Promise; Trial Design Hits Snag

By |2018-08-02T07:56:18+00:00August 2nd, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

A monoclonal antibody,BAN2401, that targets soluble amyloid-beta oligomers, slowed cognitive decline by up to 47% while clearing brain amyloid in 81% of patients with mild cognitive impairment and very mild Alzheimer’s disease, according to phase 2 study results. A joint venture with Esai and Biogen, BAN2401, is among the most promising [...]

29 06, 2018

Bipolar Medication, Lamictal, Linked with Serious Immune System Reaction

By |2018-06-29T07:28:14+00:00June 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The Food and Drug Administration has issued a warning that the seizure and bipolar medication Lamictal (lamotrigine) can cause a rare but potentially life-threatening immune response. This life-threatening immune response, known as hemophagocytic lymphohistiocytosis (HLH), causes an uncontrolled immune response and can present as a persistent fever greater than 101° F. [...]

8 06, 2018

Effects of a depression-focused internet intervention in slot machine gamblers: A randomized controlled trial

By |2018-06-08T16:28:40+00:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

By Lara Bücker , Julia Bierbrodt, Iver Hand, Charlotte Wittekind, and Steffen Moritz Background Problematic and pathological gambling have been linked to depression. Despite a high demand for treatment and negative financial consequences, only a small fraction of problematic and pathological gamblers seek professional help. The existing treatment gap could be narrowed by providing [...]

8 06, 2018

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, Trial Shows, but Decline of Clinical Symptoms Still a Question

By |2018-06-08T08:10:58+00:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called [...]

6 06, 2018

Esketamine nasal spray prevails in phase 3 trials

By |2018-06-06T07:29:40+00:00June 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

MIAMI — The combination of an esketamine nasal spray and an oral antidepressant may provide additional benefits for patients with treatment-resistant major depressive disorder, new research suggested. Two posters at a meeting of the American Society of Clinical Psychopharmacology, formerly known as the New Clinical Drug Evaluation Unit meeting, presented [...]

5 06, 2018

MDMA-Assisted Psychotherapy Improves PTSD

By |2018-06-05T15:12:24+00:00June 5th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase 2 studies show. The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) 2018 annual meeting. The pooled data from the [...]

5 06, 2018

Letter to the Editor: The Utilization of Atypical Antipsychotics in the Pain Medicine Physician’s Armamentarium

By |2018-06-08T16:47:30+00:00June 5th, 2018|Uncategorized|0 Comments

By Omar Viswanath MD Dear Editor, I read with great interest the recent article by Jimenez et al, A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/Migraine. The article states “many psychopharmacologic agents are used as primary or adjuncts in pain [...]

1 06, 2018

An Alzheimer’s Antibiotic Receives Initial Funding

By |2018-06-01T09:11:54+00:00June 1st, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

Alzheimer’s disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field, according to a posting today on FierceBiotech. The healthy sum comes after the company completed an early safety study of its [...]

24 05, 2018

Three-year Naturalistic Study On Early Use Of Long-acting Injectable Antipsychotics In First Episode Psychosis

By |2018-06-08T16:47:33+00:00May 24th, 2018|Uncategorized|0 Comments

By Sofia Medrano, Amal Abdel-Baki, Emmanuel Stip, and Stéphane Potvin Abstract Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psy- chosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these stud- ies represent a minority of patients [...]

24 05, 2018

An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature

By |2018-06-08T16:48:07+00:00May 24th, 2018|Uncategorized|0 Comments

By Marcela Almeida and Heather Burrell-Ward To the editor, We read with great interest the article by S. Thippaiah and colleagues in a recent issue of the journal. The authors reported the interesting case of a 19-year-old woman who presented with cyclical changes in mood and behavior, alternating between depression and [...]